BBOT — Bridgebio Oncology Therapeutics Cashflow Statement
0.000.00%
Last trade - 00:00- $213.26m
- -$12.45m
Annual cashflow statement for Bridgebio Oncology Therapeutics, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2023 December 31st | 2024 December 31st | 2025 December 31st | |
|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M |
| Source: | PROSPECTUS | PROSPECTUS | PROSPECTUS |
| Standards: | USG | USG | USG |
| Status: | Final | Final | Final |
| Net Income/Starting Line | -64.7 | -74.3 | -134 |
| Depreciation | |||
| Non-Cash Items | 16.5 | 3.45 | 13.4 |
| Unusual Items | |||
| Other Non-Cash Items | |||
| Changes in Working Capital | -3.94 | 15.6 | 6.43 |
| Change in Prepaid Expenses | |||
| Change in Other Assets | |||
| Change in Accounts Payable | |||
| Change in Accrued Expenses | |||
| Cash from Operating Activities | -52.1 | -55 | -114 |
| Capital Expenditures | -0.414 | -0.049 | -0.606 |
| Purchase of Fixed Assets | |||
| Other Investing Cash Flow Items | -2.41 | -120 | 73.9 |
| Change in Net Investments | |||
| Purchase of Investments | |||
| Other Investing Cash Flow | |||
| Cash from Investing Activities | -2.82 | -121 | 73.3 |
| Financing Cash Flow Items | 3.62 | 1.06 | -12.3 |
| Other Financing Cash Flow | |||
| Net Issuance / Retirement of Stock | |||
| Cash from Financing Activities | 55.1 | 206 | 383 |
| Beginning Cash Balance | |||
| Ending Cash Balance | |||
| Net Change in Cash | 0.225 | 30.7 | 343 |